1 / 25

scientific evidence to end a monopolistic market of antiretrovirals in peru

Transmission Model: Concentrated Epidemic in MSM in Peru. PROJECTED COST OF THE HAART PROGRAM. UPCH-AIS Study. Variables:Planned Coverage (for 5 years): 40%, 70%, 90%, and 95%Type of health care plan: Basic, Medium, and CompleteMedicine Type: Originator: Generic. June 2004. Costs per Death Prevented.

jacob
Download Presentation

scientific evidence to end a monopolistic market of antiretrovirals in peru

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    12. Policy Changes

    13. The Global Fund: Performance List

    19. VALIDATION OF THE BIOEQUIVALENCE AND BIOAVAILABILITY STUDIES OF LOPIMUNE The great contribution made by the Hispanic-Peruvian scientific team was irrefutable It was the first time that a study of this nature was undertaken Result: the originator and generic versions of ABBOTT and CIPLA are interchangeable

    21. Lopinavir – ritonavir puchases 2004 - 2006 Originator and Generic VersionsThe Global Fund Program

    24. The Great Lesson: To adopt a counter-current decision can be suicidal for the stability of a program like that of HAART in Peru, however, the validation of the Bioequivalence and Bioavailability studies of the generic drug Lopimune (of CIPLA) helped us not to perish in the attempt. With the approval of the users it was possible to purchase the drug and break the monopolistic market that Abbot had maintained for years. The natural consequence of this action was the reduction of Lopimune’s price, for both generic and originator versions. This happy ending would not have been possible without the Global Fund’s policies on the procurement of medicines, as well as the collaboration provided by the Clinton Foundation, Doctors Maritza Plascencia and Jesśs Frķas, and the support of the national management team of CARE Peru to the Administrative Sector of the Global Fund’s Programs.

More Related